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Abstract
Background: Human epidermal growth factor receptor (HER)-2 is a driver gene in non-small cell lung cancer
(NSCLC). The present study evaluated the mutation rate of HER-2 within the wild-type epidermal growth factor
receptor (EGFR) lung adenocarcinoma population in China.
Methods: Formalin-fixed, paraffin-embedded samples from 456 patients with wild-type EGFR lung adenocarcinoma
were analyzed for HER-2 mutations by amplification-refractory mutation system (ARMS), and HER-2 protein
expression was evaluated by immunohistochemistry. All samples positive for HER-2 mutation underwent direct
sequencing for further verification.
Results: HER-2 mutation was detected in 22/456 cases (4.8 %); the rate was 6.7 % among 331 triple-negative
samples (i.e., wild-type EGFR, anaplastic lymphoma kinase, and ROS proto-oncogene 1). Direct sequencing
confirmed that the results were consistent with those obtained by ARMS analysis in 19 cases. The positive rate was
15.4 % by immunohistochemical analysis of HER-2 expression; this was not correlated with mutation rate. HER-2
mutation and positivity were not correlated with gender, age, smoking status, disease stage, or histological subtype.
The 22 cases of HER-2 mutations occurred only in acinar (36.4 %), papillary (36.4 %), minimally invasive (13.6 %),
solid (9.2 %), and invasive mucinous (4.5 %) subtypes. Disease-free and overall survival were not associated with
HER-2 mutation or HER-2 protein overexpression.
Conclusion: The HER-2 mutation rate was 4.8 % among EGFR wild-type lung adenocarcinoma patients in China,
and 6.7 % among driver genes, triple-negative lung adenocarcinoma. The incidence of HER-2 mutation varied
among different lung adenocarcinoma subtypes, occurring mainly in acinar and papillary predominant subtypes.
15.4 % of EGFR wild-type lung adenocarcinoma patients showed HER-2 protein overexpression, but this was not
correlated to HER-2 mutation. Existing follow-up data did not show a correlation between HER-2 mutation with
DFS or OS.
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Background
Human epidermal growth factor receptor (HER)-2 is a
member of the epidermal growth factor receptor (EGFR)
family, in which it is considered as having the highest
activity. HER-2 forms heterodimers with other family
members to activate downstream mitogen-activated
protein kinase and phosphoinositide 3-kinase/Akt sig-
naling pathways [1–4]. Somatic mutations have been
identified within the kinase domain of HER-2 [5]; the
HER-2 mutation rate in non-small cell lung cancer
(NSCLC) is 2 %–4 % [6–8]. However, the relationship
between HER-2 mutation and the clinical characteris-
tics and prognosis of lung adenocarcinoma remains
unclear, not least because of inconsistencies among
findings reported by various studies. For example, some
studies have shown that HER-2 mutations were preva-
lent among non-smoking Asian females [9–11], while
another found that HER-2 mutation was related to
disease stage [12]. HER-2 protein was overexpressed in
13 %–20 % of NSCLC patients [11]; a strong positive
expression (i.e., immunohistochemistry score of 3+)
was observed in 2 %–6 % of cases [12, 13]. HER-2 overex-
pression has also been linked to poor patient prognosis
[14–16].
The present study investigated the HER-2 mutation rate
in lung adenocarcinoma patients in China with wild-type
EGFR and its relationship to clinical characteristics and
prognosis.
Methods
Patients and study design
The inclusion criteria were as follows: patients over
18 years old; confirmed diagnosis of lung adenocarcinoma;
wild-type EGFR gene; Eastern Cooperative Oncology
Group score of 0–2 points; sufficient formalin-fixed,
paraffin-embedded samples for HER-2 mutation detection
and DNA sequencing; and patient who did not receive
preoperative neoadjuvant therapy. Exclusion criteria
were as follows: patients with other tumors or severe
diseases, including psychiatric illnesses; and pregnancy.
The study protocol was approved by the Ethical Review
Committee of the Shanghai Pulmonary Hospital, and
the clinical registration number was ChiCTR-OCH-
13003507. The study design is outlined in Fig. 1.
Detection of EGFR, anaplastic lymphoma kinase (ALK),
ROS proto-oncogene (ROS) 1, and HER-2 mutations
A DNA/RNA Isolation kit (Amoy Diagnostics Co., Xiamen,
China) was used according to the manufacturer’s
instructions to extract DNA from formalin-fixed,
paraffin-embedded tissue samples. Mutations were
detected using the Human EGFR Mutation, Human ech-
inoderm microtubule-associated protein-like 4–ALK
Fusion Gene, Human ROS1 Fusion Gene, and Human
HER-2 Mutation Detection kits (Amoy Diagnostics Co.).
PCR amplification conditions were as follows: 95 °C
5 min; 15 cycles of 95 °C for 25 s and 72 °C for 20 s; and
31 cycles of 93 °C for 25 s, 60 °C for 35 s, and 72 °C for
20 s. All samples positive for HER-2 mutations were con-
firmed by DNA sequencing using primers with the follow-
ing sequences: 5'GCC ATG GCT GTG GTT TGT GAT
GG3' (forward) and 5'ATC CTA GCC CCT TGT GGA
CAT AGG3', which amplified a 342-bp fragment in exon
20 of the HER-2 gene.
Immunohistochemistry
HER-2 expression in tissue was detected using a rabbit
monoclonal anti-HER-2/Erbb2 (29D8) antibody (diluted
1:200) (Cell Signaling Technology, Danvers, MA, USA).
The intensity of the signal was determined as previously
described [10], which was as follows: 0, no staining; 1+,
< 5 % of cells with strong staining or 5 %–10 % of cells
Fig. 1 Study design. 456 cases with EGFR wild type were screened from 1316 patients and enrolled in this study
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with weak staining; 2+, 5 %–10 % of tumor cells with
strong staining or > 10 % of tumor cells with weak
staining; and 3+, > 10 % of cells with strong staining.
Membranous staining was set as the criteria, and cyto-
plasmic staining was excluded from the scoring of stain
intensity. Scores of 0/1+ and 2+/3+ were counted as nega-
tive and positive HER-2 expression, respectively. Samples
were independently evaluated by two pathologists.
Statistical analysis
SPSS v.17.0 software (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Disease-free survival (DFS)
was defined as the time between the start of surgery to
the first recorded disease recurrence/metastasis. Overall
survival (OS) was defined as the time between the start
of surgery to disease-related death. The correlations
between HER-2 mutation and clinical characteristics, as
well as between HER-2 mutation and protein expres-
sion, were evaluated with Pearson’s χ2 test or Fisher’s
exact test. Survival was analyzed with the Kaplan-Meier
test, and survival comparisons were carried out with
the log-rank test. The two-sided significance level was
set at P < 0.05.
Results
Patient characteristics
Patient characteristics are summarized in Table 1. A total
of 1316 formalin-fixed, paraffin-embedded samples from
surgical patients at Shanghai Pulmonary Hospital were ini-
tially screened, including 1107 cases of lung adenocarcin-
oma, of which 456 wild-type EGFR lung adenocarcinoma
cases were analyzed for HER-2 mutation. The final sample
set included 250 males and 206 females; the median age
was 60 years (range: 26–82 years), with 135 and 321
cases ≥ 65 and < 65 years, respectively. In addition, 295 pa-
tients had never smoked or were light smokers while 161
were heavy smokers. In terms of disease staging, 262 cases
were Stage I, 46 were Stage II, 91 were Stage III, 23
were Stage IV, and 34 were unconfirmed. The 437 cases
were classified according to lung adenocarcinoma sub-
type based on the 2011 criteria. There were 40 cases of
lepidic predominant adenocarcinoma (LPA), 187 of aci-
nar predominant adenocarcinoma (APA), 100 of papil-
lary predominant adenocarcinoma (PPA), 35 of solid
predominant adenocarcinoma (SPA), 31 of invasive mu-
cinous adenocarcinoma (IMA), 14 of adenocarcinoma
in situ (AIS), 14 of minimally invasive adenocarcinoma
Table 1 Characteristics of patients with wild-type or mutant HER-2 and positive or negative HER-2 expression by
immunohistochemistry
HER-2 WT n(%) HER-2 MUT n(%) p value HER-2 IHC(-) n(%) HER-2 IHC(+) n(%) p value
Sex Male 239(55.1) 11(50.0) 0.666 162(53.6) 30(54.5) 1.000
Female 195(44.9) 11(50.0) 140(46.4) 25(45.5)
Age ≥65 132(30.4) 3(13.6) 0.100 80(26.5) 21(38.2) 0.103
<65 302(69.6) 19(86.4) 222(73.5) 34(61.8)
Smoking status Never/light smoking 280(64.5) 15(68.2) 0.822 190(62.9) 40(72.7) 0.172
Smoking 154(35.5) 7(31.8) 112(37.1) 15(27.3)
Disease stage I 249(62.3) 13(59.1) 0.619 184(66.9) 31(62.0) 0.887
II 43(10.8) 3(13.6) 27(9.8) 5(10.0)
III 85(21.3) 6(27.3) 52(18.9) 12(24.0)
IV 23(5.8) 0(0.0) 12(4.4) 2(4.0)
Histologic subtype Lepidic 40(9.6) 0(0.0) 0.436 34(11.5) 3(5.8) 0.166
Acinar 179(43.1) 8(36.4) 126(42.7) 20(38.5)
Papillary 92(22.2) 8(36.4) 57(19.3) 12(23.1)
Micropapillary 14(3.4) 0(0.0) 12(4.1) 1(1.9)
Solid 33(8.0) 2(9.1) 20(6.8) 8(15.4)
IMA 28(6.7) 3(13.6) 24(8.1) 4(7.7)
Enteric 2(0.5) 0(0.0) 1(0.3) 1(0.2)
AIS 14(3.4) 0(0.0) 12(4.1) 0(0.0)
MIA 13(3.1) 1(4.5) 9(3.1) 3(5.8)
The total number of wild-type and mutant HER-2 cases was 456; disease stage and histologic subtype data were available for 422 and 437 of these
cases, respectively
The total number of cases negative or positive for HER-2 by immunohistochemistry was 357; disease stage and histologic subtype data were available for 325 and
347 cases, respectively
Abbreviations: AIS adenocarcinoma in situ, IMA invasive mucinous adenocarcinoma, MIA minimally invasive adenocarcinoma
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(MIA), 14 of micropapillary predominant adenocarcin-
oma (MPA), and two of enteric adenocarcinoma (EA).
HER-2 mutation rate
ARMS analysis was used to detect HER-2 exon 20 muta-
tions in 456 cases of wild-type EGFR lung adenocarcin-
oma; 22 (4.8 %) were found to be positive. The presence
of an echinoderm microtubule-associated protein-like 4/
anaplastic lymphoma kinase (ALK)–ROS proto-oncogene
(ROS) 1 fusion gene was also examined in 390 cases; 331
were found to harbor wild-type ALK/ROS1. The HER-2
mutation rate in patients with wild-type EGFR/ALK/
ROS1 (i.e., triple-negative samples) was 6.7 %; the 22
samples were analyzed by PCR combined with direct se-
quencing. For three of the samples, sequencing failed due
to insufficient sample quantity. Results for the remaining
19 samples were consistent with those obtained by ARMS:
13 cases were 2324_2325 ins12 (atacgtgatggc), three were
2326_2327insTGT, two were 2325_2326 ins12 (tacgt-
gatggct), and one was 2331_2332 ins9 (ggctcccca) (Fig. 2).
Analysis of HER-2 protein expression
HER-2 protein expression was assessed in 357 samples
by immunohistochemistry. Results were interpreted as
previously described [10]. There were 55 positive sam-
ples (15.4 %), of which 43 were 2+ (12.0 %) and 12 were
3+ (3.4 %) (Fig. 3).
Relationship between HER-2 mutation and protein expres-
sion and clinical characteristics
The presence of HER-2 mutations was not correlated with
clinical characteristics, including gender, age, smoking sta-
tus, histological subtype, and disease stage. However, the
mutation rate differed among lung adenocarcinoma sub-
types: the 22 cases of HER-2 mutation were observed in
APA (36.4 %), PPA (36.4 %), MIA (13.6 %), SPA (9.2 %),
and IMA (4.5 %), whereas no mutations were detected in
LPA, MPA, EA, or AIS (Table 1 and Fig. 4). Furthermore,
there was no correlation between HER-2 mutation and
protein expression. Simultaneous HER-2 mutation and
HER-2 overexpression was observed in only two samples.
Relationship between prognosis and HER-2 mutation or
protein expression
At the last follow-up, 123 patients achieved DFS, and OS
data were collected from 39 patients. Most of the
remaining patients continued to survive, and follow-up
data are needed. A subset of patients was lost to follow-
up. HER-2mutation was not associated with DFS (median:
16.7 vs. 17.0 months; P = 0.966). The difference with OS
was also not statistically significant (median: 34.2 vs.
47.6 months; P = 0.844). DFS data were obtained from 79
and 17 patients who were negative and positive for
HER-2, respectively, by immunohistochemistry. How-
ever, DFS did not differ significantly between the two
groups (median: 14.4 vs. 12.8 months, P = 0.238). The
14 HER-2-negative and one HER-2-positive patients
Fig. 2 The confirmed results of HER-2 mutations by DNA sequencing. a HER-2 wild type; b The arrow showed HER-2 A755_G776insYVMA
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had similar OS (median: 24.9 vs. 48.0 months, P = 0.075)
(Fig. 5). We also analyzed the DFS data of the HER2
IHC(-) versus HER2 IHC (+) in stage I/II and stage III/IV
cases, respectively (Additional file 1: Figure S1) and found
that none of them had a significantly difference.
Discussion
In the present study, HER-2 mutation rate and protein ex-
pression level were measured in 456 patients with wild-
type EGFR lung adenocarcinoma. The HER-2 mutation
rate was 4.8 % while the rate in EGFR/ALK/ROS1 triple-
negative samples was 6.7 %. There was no correlation be-
tween HER-2 mutation and clinical characteristics. The
rate differed according to lung adenocarcinoma subtype
and was highest in APA (36.4 %) and PPA (36.4 %).
HER-2 mutations have been linked to NSCLC. Other
studies have shown that they also occur in lung adenocar-
cinoma, with mutation rates from 2 % up to 14.1 % [9, 10,
17]. Our results were consistent with previous studies
reporting a HER-2 mutation rate of 1.98 % in the overall
population, 4.8 % in wild-type EGFR cases, and 6.7 % in
EGFR/ALK/ROS1 triple-negative cases. The most com-
monly observed HER-2 mutation is an in-frame insertion
in exon 20 [6]. An analysis of HER-2 mutations in exons
18–21 identified cases harboring the same exon 20 inser-
tion [10]. In the present study, DNA sequencing of 19 pa-
tients revealed 15 cases with A775_G776ins12YVMA,
three with 2326_2327insTGT, and one with 2331_2332
ins9 (ggctcccca), all of which are in exon 20. HER-2 inhibi-
tors such as trastuzumab and afatinib were effective in
inhibiting exon 20 insertion mutations [18, 19], which are
thus a useful biomarker for assessing the therapeutic effi-
cacy of these inhibitors.
Fig. 3 HER-2 protein expression in EGFR wild type lung adenocarcinoma patients by immunohistochemistry: A.0 B.1+ C.2+ D.3+
Fig. 4 Histologic subtype distribution of the 437 EGFR wild type and
22 HER-2 mutation samples. a Acinar and papillary are the most
common histologic subtypes in lung adenocarcinoma; b HER-2
mutations occurred in acinar, papillary, solid, IMA, and MIA subtypes,
other subtypes were not found (IMA, invasive mucinous
adenocarcinoma; MIA, minimally invasive adenocarcinoma)
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HER-2 mutations are more common in female non-
smokers with moderately to poorly differentiated adeno-
carcinoma, small tumor load, and early-stage lung cancer,
but are not linked to patient prognosis [10, 11, 17]. Two
studies in the Chinese population also found that HER-2
mutations were prevalent in female non-smokers, but
were not correlated with prognosis [10, 20], while a study
from Taiwan found an association between HER-2 muta-
tion and late stages of disease [8]. We did not observe a
correlation between mutation status and patient charac-
teristics such as gender, age, disease stage, smoking status,
or prognosis.
APA and PPA subtypes of lung adenocarcinoma
accounted for 65.7 % of all cases examined in this
study. These results are consistent with those reported
by others; for instance, among Caucasians, HER-2 mu-
tations were primarily observed in PPA, APA, SPA, and
MPA [9], whereas another study found that mutation
rates were higher in PPA, AIS/MPA, LPA, and SPA
[11]. Thus, HER-2 mutations are mainly associated with
APA, PPA, IMA, SPA, and MIA subtypes with some
similarity across ethnic groups; HER-2 inhibitors may
be effective in such patients. Therefore, more emphasis
should be placed on the classification of lung adenocar-
cinoma histological subtypes and HER-2 mutation ana-
lysis in clinical settings.
Conclusions
In summary, this study showed that HER-2 mutation
was not correlated to HER-2 protein overexpression, and
existing follow-up data did not show a correlation be-
tween HER-2 mutation with DFS or OS.
Additional file
Additional file 1: Figure S1. DFS of HER-2 IHC (-)/(+) patients in stage
I/II and III/IV. A. DFS of HER-2 IHC (-) (n = 45) and IHC (+) (n = 10) patients
in stage I/II. B. DFS of IHC (-) (n = 31) and IHC (+) (n = 6) patients in stage
III/IV. (TIF 1145 kb)
Abbreviations
AIS: Adenocarcinoma in situ; ALK: Anaplastic lymphoma kinase; APA: Acinar
predominant adenocarcinoma; ARMS: Amplification-refractory mutation
system; DFS: Disease-free survival; EA: Enteric adenocarcinoma;
EGFR: Epidermal growth factor receptor; HER-2: Human epidermal growth
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Fig. 5 DFS and OS were analyzed according to HER-2 mutations status and protein expression level, respectively. a DFS of HER-2 WT (n = 114)
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adenocarcinoma; ROS1: ROS proto-oncogene 1; SPA: Solid predominant
adenocarcinoma
Acknowledgements
We thank Dr. Chunyan Wu and Dr. Dongmei Lin for the histologic subtype
analysis.
Funding
The study was supported by research grants from Boehringer Ingelheim
(China, Protocol No. 1200.192) and grants from the National Natural Science
Foundation of China (No. 81401890, No.81372392, No. 81402486).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
XL and CZ contributed equally in preparing and conducting this research.
CS, SR and XC provided the patient information and followed the patient
survival data. CZ designed and coordinated the research in the whole
process. All authors read and approved the final manuscript.
Competing of interest
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was approved by the Ethical Review Committee of the
Shanghai Pulmonary Hospital. Written informed consent was obtained from
the patient for publication of this report and any accompanying tables and
images.
Author details
1Department of Lung Cancer and Immunology, Shanghai Pulmonary
Hospital, Tongji University, No. 507 Zhengmin Road, Shanghai 200433,
People’s Republic of China. 2Department of Medical Oncology, Shanghai
Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji
University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433,
People’s Republic of China.
Received: 25 May 2016 Accepted: 24 October 2016
References
1. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred
heterodimerization partner of all ErbB receptors, is a mediator of lateral
signaling. EMBO J. 1997;16(7):1647–55.
2. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell
lung cancer. J Clin Oncol. 2013;31(8):1097–104.
3. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP,
Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation
and human mammary carcinomas. Oncogene. 1995;10(9):1813–21.
4. Spector NL, Blackwell KL. Understanding the mechanisms behind
trastuzumab therapy for human epidermal growth factor receptor 2-positive
breast cancer. J Clin Oncol. 2009;27(34):5838–47.
5. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C,
O'Meara S, Smith R, Parker A, et al. Lung cancer: intragenic ERBB2 kinase
mutations in tumours. Nature. 2004;431(7008):525–6.
6. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B,
Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2
mutation: epidemiologic characteristics and therapeutic perspectives. J Clin
Oncol. 2013;31(16):1997–2003.
7. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II,
Chen H, Fujimoto J, Kugler K, Franklin WA, et al. Multi-institutional
oncogenic driver mutation analysis in lung adenocarcinoma: the lung
cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768–77.
8. Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, Chiu KL, Yang TY, Chen
KC, Ooi H, et al. Identification of five driver gene mutations in patients
with treatment-naive lung adenocarcinoma in Taiwan. PloS One.
2015;10(3):e0120852.
9. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK,
Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations,
and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung
adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–8.
10. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, et
al. Lung adenocarcinomas with HER2-activating mutations are associated
with distinct clinical features and HER2/EGFR copy number gains. J Thorac
Oncol. 2012;7(1):85–9.
11. Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, Furuta K,
Kohno T, Tsuta K. HER2 gene mutations in non-small cell lung carcinomas:
concurrence with Her2 gene amplification and Her2 protein expression and
phosphorylation. Lung Cancer. 2015;87(1):14–22.
12. Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist
YK, Klose H, Marx AH, Koops S, Simon R, et al. Heterogeneity of ERBB2
amplification in adenocarcinoma, squamous cell carcinoma and large cell
undifferentiated carcinoma of the lung. Mod Pathol. 2012;25(12):1566–73.
13. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C,
Baron A, Bunn Jr PA. Evaluation of HER-2/neu gene amplification and
protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;
86(9):1449–56.
14. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM,
Delmotte P, Lafitte JJ, Sculier JP. The role of HER-2/neu expression on the
survival of patients with lung cancer: a systematic review of the literature. Br
J Cancer. 2003;89(6):959–65.
15. Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, Yin Y, Liu P, Shu Y. The role of
human epidermal growth factor receptor 2 as a prognostic factor in lung
cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5(12):1922–32.
16. Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S,
Shigematsu Y, Nagata Y, Shimokawa H, Nakagawa M, et al. The prognostic
significance of HER2 overexpression in non-small cell lung cancer.
Anticancer Res. 2011;31(12):4631–6.
17. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, Shigematsu
H, Kuwano H, Yatabe Y, Mitsudomi T. Prognostic and predictive
implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung
Cancer. 2011;74(1):139–44.
18. Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis
N. HER2 insertion YVMA mutant lung cancer: Long natural history and
response to afatinib. Lung Cancer. 2015;90(3):617–9.
19. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S,
Brandstetter KA, Kubo S, et al. HER2YVMA drives rapid development of
adenosquamous lung tumors in mice that are sensitive to BIBW2992 and
rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009;106(2):474–9.
20. Bu S, Wang R, Pan Y, Yu S, Shen X, Li Y, Sun Y, Chen H. Clinicopathologic
Characteristics of Patients with HER2 Insertions in Non-small Cell Lung
Cancer. Ann Surg Oncol. 2016. [Epub ahead of print].
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. BMC Cancer  (2016) 16:828 Page 7 of 7
